Turnstone Biologics Corp. (TSBX) Research

Turnstone Biologics Corp. is a clinical-stage biotechnology firm dedicated to developing therapeutic and curative treatments for patients battling solid tumor cancers. Its leading investigational drug, TIDAL-01, is currently undergoing Phase 1 clinical trials for indications such as breast cancer, colorectal cancer, and uveal melanoma. This compound is also being assessed in an investigator-sponsored trial to address cutaneous and non-cutaneous melanomas. Furthermore, the company is advancing TIDAL-02, which is in preclinical development for treating various solid tumors. Turnstone Biologics was established in 2014 and maintains its headquarters in La Jolla, California.

Market snapshot

Symbol
TSBX
Price
$0.36
Day change
0.00%
Market cap
$8.2M
P/E ratio
-0.27x
52-week range
0.29-2.2614
Sector
Healthcare
Industry
Biotechnology
Analyst price target
$0.50

Peer companies

  • Apexigen, Inc. (APGN)
  • Biora Therapeutics, Inc. (BIOR)
  • Channel Therapeutics Corporation (CHRO)
  • CervoMed Inc. (CRVO)
  • COSCIENS Biopharma Inc. (CSCI)
  • IMV Inc. (IMVIF)
  • Kineta, Inc. (KA)
  • Omega Therapeutics, Inc. (OMGA)

Recent insider activity

  • ORBIMED ADVISORS LLC — U-Tender (3099265 shares) on 2025-08-08
  • Versant Ventures V, LLC — U-Tender (274990 shares) on 2025-08-08
  • Jerel Davis — U-Tender (82006 shares) on 2025-08-08
  • Gupta Rishi — U-Tender (3099265 shares) on 2025-08-08
  • Rajangam Kanya — A-Award (12770 shares) on 2024-06-03

Open Turnstone Biologics Corp. (TSBX) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.